基于结构的药物设计,针对MexB的基质结合口袋
1Department of Biochemistry, School of Life Science, JSS Academy of Higher Education and Research, Longwood Campus, Mysuru Road, Ooty, India. praveenananjan29@gmail.com.
The protein journal
|February 18, 2026
概括
耐多药性Pseudomonas aeruginosa感染是一个主要的威胁. 这项研究探讨了针对MexB转运器的新型排泄抑制剂 (EPI),以克服这种耐药性并恢复抗生素的有效性.
科学领域:
- 微生物学 微生物学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- Pseudomonas aeruginosa 呈现多药性耐药性 (MDR),这是一个重大的临床挑战.
- 流出,特别是像MexAB-OprM这样的阻力结节分裂 (RND) 系统,是这种MDR表型的关键.
- 在MexAB-OprM排泄系统中,MexB是关键的内膜载体,负责识别和结合各种抗生素.
研究的目的:
- 调查针对P. aeruginosa的RND型排泄系统的新型排泄抑制剂 (EPI).
- 为了应对药物设计结构和计算工具的有限访问的挑战.
- 讨论与MexB传送器相关的最近的结构发现.
主要方法:
- 关于P. aeruginosa排泄和EPI的现有文献的审查.
- 分析与MexB.相关的结构数据和计算研究.
- 检查开发新型EPI的潜在策略.
主要成果:
- 由于其在挤出广泛的抗生素中的作用,MexB是开发EPI的验证目标.
- 墨西哥AB-OprM系统的过度表达受到特定基因 (mexR,nalC,nalD) 的调节.
- 抗生素和EPI的联合治疗显示出通过增加细胞内药物度来恢复抗菌活性的潜力.
结论:
- 开发针对MexB的EPI是对抗MDR P. aeruginosa感染的有希望的战略.
- 结构生物学和计算工具的进步对于合理的EPI设计至关重要.
- 新型EPI可以使细菌对现有抗生素重新敏感,从而提供新的治疗途径.
相关概念视频
Targets for Drug Action: Overview
10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Ligand Binding and Linkage
5.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.7K
Protein-Drug Binding: Mechanism and Kinetics
1.9K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.9K


